Jamie Macdonald is Chief Executive Officer of Parexel. Mr Macdonald has more than 25 years of experience in leading global biopharmaceutical services companies. Prior to joining Parexel, he served as Chief Executive Officer of INC Research, now known as Syneos Health, from January 2013 through September 2016, where he led the company through a successful Initial Public Offering in 2014. Mr Macdonald also served as INC’s Chief Operating Officer from July 2011 through December 2012, and previously held several leadership positions in the biopharmaceutical services industry, including Senior Vice President and Head of Global Project Management at Quintiles, now known as IQVIA. Prior to this, he held various senior operational and finance roles at Quintiles. He has previously served on the Board of Directors for the Association of Clinical Research Organizations (ACRO) and as its Chairman in 2015. Mr Macdonald’s recent experience also includes serving as Chairman of the Board for Certara, a drug development consultancy with solutions spanning discovery, preclinical and clinical drug development, from 2017 to 2018.

Mr Macdonald began his career in the pharmaceutical industry with Syntex Corporation (acquired by Roche Holdings, Inc.). A native of Scotland, he holds a BA in Economics from Heriot-Watt University in Edinburgh, Scotland and is a qualified Chartered Management Accountant (ACMA).

Matt W. Maddox is Associate Vice President in IDS at Eli Lilly and Company. In his role, Mr Maddox is responsible for leveraging innovative technology to transform and run clinical development of Lilly’s late-stage drug portfolio. Key areas of focus include Automation, Advanced Analytics, User Experience and Service Management.

Mr Maddox has deep expertise in Global IT Management, Clinical Development, Advanced Analytics, Sales and Marketing Enablement as well as Mobile Solution Delivery. His passion to transform the pharmaceutical industry through technology as well as his people first approach to leadership provide his foundation to drive innovation.

Mr Maddox earned his undergraduate degree in Business from Indiana University. Mr Maddox lives in Indianapolis with his wife and 4 children and is passionate about being outdoors, travel and red wine.

Paul Mancinelli, PhD, is the Chief Technology Officer of WCG where he leads technology overall, including infrastructure, software engineering, and application development across the organization to support WCG’s strategy and enhance productivity, efficiency, and synergy throughout the enterprise.

Dr Mancinelli previously served as Cigna’s Chief Data and Analytics Engineering Officer where he was responsible for Cigna’s enterprise authoritative data assets as well as the advanced analytics ecosystem and reporting solutions. Under his leadership, the Data & Analytics Engineering team was a catalyst for the use of Big Data, Machine Learning and Open Source technologies in support of Cigna’s Personalization and Affordability strategies.

Ingrid A. Mayer, MD, MSCI is the Breast Cancer Global Clinical Strategy Head at AstraZeneca Late Development Oncology. After 20 years in academia and clinical practice as a breast cancer medical oncologist, her current role is to pioneer and expand novel translational global research and innovative clinical trial development in breast cancer that accelerates the approval of established and novel drugs in the key areas of excellence at AstraZeneca, tumor resistance/ targeted therapies, DNA damage response, antibody-drug conjugates, and immuno-oncology. Before joining AZ, Dr Mayer was a Professor of Medicine and Ingram Professor of Cancer Research at Vanderbilt University Medical Center with a successful track record of phase I, II and III clinical trials and has chaired, co-chaired or been a member of many national and international health services cancer leadership committees in the US, such as ECOG-ACRIN Breast Core Committee, National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, Translational Breast Cancer Research Consortium (TBCRC) amongst many others. Her translational research focused on identifying targetable pathways and mechanisms of treatment resistance in breast cancer, which have been recognized and funded by the NCI (K23 and SPORE in Breast Cancer), SU2C/ AACR, Susan G. Komen Foundation and the Breast Cancer Research Foundation and published in more than 130 peer-reviewed journals.

Jean McCoy, EVP, Partnerships for Reverba and accelerates the company’s growth by ensuring they are dependable partners who are consistently bringing value to their clients. Her knowledge of what this requires is based on more than 25 years of leadership in biopharmaceutical marketing and commercialization. She is an outspoken authority on patient engagement who frequently gives keynote addresses about our pioneering work in both the commercial and clinical arenas.

Kelly McKee is the Head of Innovative Recruitment at Evinova, AstraZeneca’s digital healthcare company where she is responsible for leading the department to develop and deploy digital and innovative patient recruitment strategies and tactics.  Kelly is a proven clinical trial leader and trailblazer in operationalizing global patient-focused solutions. Prior to Evinova, she spent over 20 years in clinical operations, digital technology, and patient recruitment at top-tier companies, including Sanofi, Merck, Eli Lilly and Co., Medidata, and Vertex Pharmaceuticals.

Sarah McKeown-Cannon (she/her) is the Senior Vice President and Head of Clinical Research at Heartbeat, where she is flipping the script on traditional recruitment and retention. Heartbeat isn’t in the business of chasing referrals or measuring success by vanity metrics. Instead, Sarah leads the charge in fixing the “leaky funnel” once and for all—by shifting the focus to patient activation. At Heartbeat Clinical Research, Sarah and her team meet patients where they are, ensuring they aren’t just found but are ready, willing, and empowered to take action. This means moving beyond outdated recruitment tactics and instead designing sustained engagement strategies that transform passive candidates into active participants in their own health journey. Her commitment to health equity is evident in every initiative she leads—ensuring that underrepresented communities aren’t just included in research but are centered in it. As Co-Chair of the Reflections collective, she extends this work even further, driving industry-wide change for more inclusive, patient-first clinical trials. A MM&M 40 Under 40 honoree, Sarah bridges global healthcare intelligence with deep behavioral insights, ensuring every study doesn’t just recruit but activates. Through her bold vision and relentless leadership, she is shaping the future of clinical research—one where patients aren’t just participants but powerful advocates in their own care.

Hope Meely is the Chief Clinical Officer at Slope, the industry-leading provider of a clinical trial execution platform for highly complex, sample-intensive clinical trials. Ms Meely has spent the entirety of her 25-year clinical research career supporting several sponsors and CROs in leading clinical operations teams in the execution of their clinical trial programs. Most recently, Ms Meely spent 3 years in a growing biotech leading operations for a robust early phase oncology pipeline. She is passionate about making clinical trial operations easier for research sites, sponsors, and other collaborators.

Matt Michelson is a co-founder and the CEO of Readout AI. An expert in AI and machine-learning, Dr Michelson has been in the field for nearly a decade, both as a venture-backed founder and executive, and as a researcher, publishing more than 35 peer-reviewed articles in scientific conferences and journals. He has been involved in two start-up exits: first as CEO of Evid Science, which was sold to Genesis Research, and later as President of Genesis AI, when Genesis Research itself was sold to GHO Capital. Dr Michelson holds an MS and PhD in Computer Science from the University of Southern California, and a BS in Computer Science from Johns Hopkins University.

Shannon Miller competed in TWO Olympic Games, earning 7 Olympic medals! (2 gold, 2 silver, 3 bronze). She is the only female athlete to be inducted into the US Olympic Hall of Fame – Twice! (Individual (2006) and Team (2008))

Shannon is the first US gymnast to win 2 World All-Around Titles. Her tally of five medals (2 silver, 3 bronze) at the 1992 Olympics was the most medals won by a US athlete in any sport. At the ’96 Games, she led the “Magnificent Seven” to the US Women’s first ever Team Gold and for the first time for any American gymnast, she captured Gold on the Balance Beam.

After retiring from Olympic competition, Shannon received her undergraduate degrees in marketing and entrepreneurship from the University of Houston and her law degree from Boston College.

Shannon remains a part of the gymnastics and Olympic communities as an analyst and commentator. In 2010, Shannon launched her company devoted to helping women make their health a priority. She continues to travel the country as a highly sought-after motivational speaker on topics ranging from The Gold Medal Mindset to cancer and survivorship and to the importance of health and fitness.

In January of 2011, Shannon was diagnosed with a rare form of ovarian cancer. She had the baseball sized tumor removed successfully and followed up with an aggressive chemotherapy regimen. Shannon is currently cancer-free and continues to be a strong advocate for early detection, awareness, research and survivorship.

For more than 20 years, Lisa Moneymaker has been a leader in the pharma, biotech, and medical device industries. Ms Moneymaker’s leadership has delivered complex systems solutions in support of excellence in clinical trial execution.Prior to joining Saama, Ms Moneymaker was SVP of Clinical Operations Technology at Medidata Solutions. In this position, she helped to advance the role of internal sponsor and CRO technology in support of Decentralized Clinical Trials, as the industry responded to the pressures of an increasingly remote world.Ms Moneymaker began her career at Accenture and continued as an independent consultant, gaining exposure to information systems across the pharma space. Much of her career was in support of Amgen, developing systems within its global development organization, which gained her exposure and recognition as a subject matter expert within pharma information systems. A graduate of University of Southern California, she holds a BS in Biomedical Biochemical Engineering.

Scott Morris is VP and General Manager for Clinical Trial Solutions of Optum Life Sciences. Mr Morris has significant experience in healthcare and technology across life sciences, research, and provider market segments and is uniquely qualified to understand the challenges and lead the delivery of support offerings to accelerate and diversify clinical trials participation and streamline processes to help bring new therapies to market for the patients who need them. Most recently, he served as Vice President – Health Sciences at Change Healthcare, prior to its acquisition by Optum. He has also held various leadership roles at IQVIA (formerly Quintiles) plus related ventures, Oracle Health Sciences and Premier, Inc. and has demonstrated success in developing and growing new business offerings and partnerships in the context of larger organizations.

Mr Morris received his Bachelor of Science in Marketing from the Wilbur O. and Ann Powers College of Business at Clemson University with additional emphasis in Computer Science and Math. He also completed an Executive Leadership Program at the Kenan-Flagler Business School at UNC-Chapel Hill.

Mr Morris continues to serve Clemson University as a member of its Board of Visitors, has served on a global non-profit board, and is involved in various industry groups, including DIA. He is active in his community and other service opportunities while enjoying his family, outdoor activities, collegiate events, and live music.